Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 1, 2014, Pages 132-135

  Hotze, M ^a   Baurecht, H ^a,b   Rodriguez E ^a   Chapman Rothe, N ^c   Ollert, M ^b   Folster Holst R ^a   Adamski, J ^b,d   Illig, T ^e   Ring, J ^b   Weidinger, S ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c NOVARTIS PHARMA GMBH   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

anti IgE; atopic dermatitis; filaggrin; metabolomics; omalizumab

Indexed keywords

ACYLCARNITINE; AMINO ACID; CARBOHYDRATE; EMOLLIENT AGENT; FILAGGRIN; GLYCEROPHOSPHOLIPID; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB; PHOSPHATIDYLCHOLINE; SPHINGOMYELIN; STEROID; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; AUTOIMMUNITY; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; IMMUNOTHERAPY; LUNG LAVAGE; MALE; MULTIPLE CYCLE TREATMENT; OPEN STUDY; PILOT STUDY; PLACEBO EFFECT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION; TH2 CELL; TREATMENT DURATION; TREATMENT RESPONSE;

ANTI-IGE; ATOPIC DERMATITIS; FILAGGRIN; METABOLOMICS; OMALIZUMAB;

ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATITIS, ATOPIC; HUMANS; INTERMEDIATE FILAMENT PROTEINS; PHOSPHATIDYLCHOLINES; TREATMENT OUTCOME;

EID: 84892769446     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12234     Document Type: Article

References (18)

1. Garmhausen D, Hagemann T, Bieber T, Dimitriou I, Fimmers R, Diepgen T, et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy 2013; 68: 498-506.
2. Novak N, Simon D,. Atopic dermatitis-from new pathophysiologic insights to individualized therapy. Allergy 2011; 66: 830-839.
3. Bieber T,. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy 2012; 67: 1475-1482.
4. Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 2011; 66: 671-678.
5. Groffik A, Mitzel-Kaoukhov H, Magerl M, Maurer M, Staubach P,. Omalizumab-an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy 2011; 66: 303-305.
6. Lavaud F, Bonniaud P, Dalphin JC, Leroyer C, Muller D, Tannous R, et al. Usefulness of omalizumab in ten patients with severe occupational asthma. Allergy 2013; 68: 813-815.
7. Tillie-Leblond I, Germaud P, Leroyer C, Tétu L, Girard F, Devouassoux G, et al. Allergic bronchopulmonary aspergillosis and omalizumab. Allergy 2011; 66: 1254-1256.
8. Kopp MV,. Role of immunmodulators in allergen-specific immunotherapy. Allergy 2011; 66: 792-797.
9. Babu KS, Polosa R, Morjaria JB,. Anti-IgE-emerging opportunities for Omalizumab. Expert Opin Biol Ther 2013; 13: 765-777.
10. Ried JS, Baurecht H, Stückler F, Krumsiek J, Gieger C, Heinrich J, et al. Integrative genetic and metabolite profiling analysis suggests altered phosphatidylcholine metabolism in asthma. Allergy 2013; 68: 629-636.
11. Wymann MP, Schneiter R,. Lipid signalling in disease. Nat Rev Mol Cell Biol 2008; 9: 162-176.
12. Cottrell L, Neal WA, Ice C, Perez MK, Piedimonte G,. Metabolic abnormalities in children with asthma. Am J Respir Crit Care Med 2011; 183: 441-448.
13. Almstrand AC, Josefson M, Bredberg A, Lausmaa J, Sjövall P, Larsson P, et al. TOF-SIMS analysis of exhaled particles from patients with asthma and healthy controls. Eur Respir J 2012; 39: 59-66.
14. Lundström SL, Yang J, Källberg HJ, Thunberg S, Gafvelin G, Haeggström JZ, et al. Allergic asthmatics show divergent lipid mediator profiles from healthy controls both at baseline and following birch pollen provocation. PLoS ONE 2012; 7: e33780.
15. Fuchs B, Schiller J, Wagner U, Häntzschel H, Arnold K,. The phosphatidylcholine/lysophosphatidylcholine ratio in human plasma is an indicator of the severity of rheumatoid arthritis: investigations by 31P NMR and MALDI-TOF MS. Clin Biochem 2005; 38: 925-933.
16. Jahnz-Rozyk K, Targowski T, Paluchowska E, Owczarek W, Kucharczyk A,. Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis. Allergy 2005; 60: 685-688.
17. Morita E, Takahashi H, Niihara H, Dekio I, Sumikawa Y, Murakami Y, et al. Stratum corneum TARC level is a new indicator of lesional skin inflammation in atopic dermatitis. Allergy 2010; 65: 1166-1172.
18. Rabe KF, Calhoun WJ, Smith N, Jimenez P,. Can anti-IgE therapy prevent airway remodeling in allergic asthma? Allergy 2011; 66: 1142-1151.